CClinicalTrials.gg
Sign In
Status unknownNCT03413293Updated May 18, 2018

Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients

An observational study in Nosocomial Infection, sponsored by Assiut University. Status unknown. Per ClinicalTrials.gov, last updated 2018-05-18.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
20
Sex
All
01

Study summary

Hospital acquired chest Infections are common complications in hospitalized cirrhotic patients. Infectious complications are the most common cause of mortality in cirrhotic patients with bronchopneumonia early antibiotic treatment at the base of culture and sensitivity is an optimal therapeutic approach in cirrhotics with nosocomial pneumonia Intensive care unit acquired pneumonia is the leading infection in critically ill patients and a major cause of morbidity and mortality despite recent major advances in antimicrobial therapy, supportive care, and the use of a broad range of preventive measures

Read the detailed description

Aim of the work

  1. To estimate the frequency and risk factors of nosocomial chest infections in cirrhotic patients .
  2. To determine the causative pathogens of nosocomial chest infections in patients with cirrhosis including fungal infections in order to establish our local empirical antimicrobial protocol.
  3. To define the impact of nosocomial chest infections on survival of our patients.
  4. To develop an effective and continuous surveillance program and infection control measures to reduce the burden of these infections as well as morbidity , mortality , hospital stay ,hospital cost and to achieve quality of care .
  5. To motivate pharmaceutical companies to create a new umbrella coverage of antimicrobials through the ongoing knowledge of the changes in microbial resistance pattern inside hospitals
02

Conditions studied

  • Nosocomial Infection
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patient were known to have liver cirrhois and admitted at hospital secondary to any cause

Inclusion criteria

  • All cirrhotic patients , decompensated , child pug score B or C ,may have Hepatocellular carcinoma , other comorbidities may present as (Diabetius mellitus , Hypertension , Heart disease and renal impairment ) , both sex and with clinical suspicion of chest infections acquired after 48 hours of admission

Exclusion criteria

Exclusion Criteria:

  • Patients have any chronic chest disease
  • Patients have severe immunosuppression (neutropenia after chemotherapy or hematopoietic transplant, drug-induced immunosuppression in solid-organ transplant or cytotoxic therapy, and HIV-related disorders.
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Nosocomial infected cirrhotic patients

    Diagnostic Test: Diagnosis of bacterial infections

Interventions

  • Diagnostic testDiagnosis of bacterial infections

    Cultures

05

What researchers measure

Primary outcomes

  1. Frequency of nosocomial infection in patients with liver cirrhosis

    nosocomial infection is one of predictors of bad outcome in liver cirrhosis

    Time frame: baseline

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Di Pasquale M, Esperatti M, Crisafulli E, Ferrer M, Bassi GL, Rinaudo M, Escorsell A, Fernandez J, Mas A, Blasi F, Torres A. Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study. Intensive Care Med. 2013 Oct;39(10):1776-84. doi: 10.1007/s00134-013-3025-6. Epub 2013 Aug 2. PubMed 23907496 ↗
08

Registry details

Key details

Study ID
NCT03413293
Lead sponsor
Assiut University
Responsible party
NZBakhiet (resident doctor, Assiut University) — Principal investigator
First posted
Jan 29, 2018
Start date
Jun 2018 (estimated)
Primary completion
May 2019 (estimated)
Completion
Aug 2019 (estimated)
Last update
May 18, 2018

Study contacts

Nariman zaghluol bakhiet, postgraduate
Contact
narimandoctor@yahoo.com
01005546130

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infections→

Other studies from this sponsor

Assiut University

Start the discussion